New developments in osteoporosis treatments.
Miller
C A
CA
Miller/Wetzler Associates, Cleveland, Ohio, USA.
D000368:Aged; D019386:Alendronate / Q000627:therapeutic use; D002116:Calcitonin / Q000627:therapeutic use; D015914:Estrogen Replacement Therapy / Q000009:adverse effects; D005260:Female; D006801:Humans; D015663:Osteoporosis, Postmenopausal / Q000517:prevention & control*; D020849:Raloxifene Hydrochloride / Q000627:therapeutic use; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use; D013629:Tamoxifen / Q000627:therapeutic use
D020845:Selective Estrogen Receptor Modulators; D013629:Tamoxifen; D020849:Raloxifene Hydrochloride; D002116:Calcitonin; D019386:Alendronate